Application of PDPN positive macrophages in preparation of sepsis treatment medicine
By isolating and studying PDPN-positive peritoneal macrophages regulated by ADAP in a sepsis mouse model, it was found that these cells exhibited M2 polarization phenotype and high phagocytosis activity, which solved the unclear problem of the function of these cells in the prior art and achieved effective application in sepsis treatment drugs.
Patent Information
- Application Number
- CN202411891233.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-12-19
- Filing Date
- 2024-12-20
- Publication Date
- 2025-03-21
AI Technical Summary
At present, the biological characteristics, functions and their specific roles in the pathological process of sepsis are still unclear, and the prior art is difficult to effectively utilize these cells in the preparation of sepsis treatment drugs.
By constructing a sepsis mouse model, macrophages with high expression of surface PDPN protein were isolated from the abdominal cavity, and the expression of PDPN protein was regulated by ADAP protein. This type of PDPN-positive peritoneal macrophage showed a macrophage M2 polarization phenotype. The expression level of M2-type polarization-related marker genes was verified by RNA-seq, and the phagosomal signaling pathway was significantly enriched in PDPN-positive macrophages.
During the host's resistance to bacterial infection with sepsis, PDPN-positive macrophages exhibit high phagocytosis activity and have the potential to prepare sepsis therapeutic drugs.